Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE)…
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA / SOFTAG breast implant
24-month Phase I follow-up data show positive outcomes are maintained High levels of…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
Tekton Research Expands Clinical Network with Three New Sites, Five New Investigators, and CNS Thought Leader
AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Sapu Nanos Sapu003 Advances to Human Clinical Testing – Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full…
MindHYVE.ai Unveils ChironAI: The World’s First AGI-Powered Clinical Decision Support System, Redefining Healthcare Intelligence
NEWPORT BEACH, Calif., Sept. 24, 2025 /PRNewswire/ -- HYVE Labs™ and MindHYVE.ai™…
Osstem Implant Expands World-Class Clinical Education in India, Accelerating CSR Efforts
OIC India Enhances On-Site Capabilities with Structured Clinical and Digital Dentistry Training…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
